StockData
Latigo Biotherapeutics, Inc. logo

Latigo Biotherapeutics, Inc. (LTGO) stock

LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.76+1.16 (+9.21%)

Close on Nov 17, 2026Market cap $912.28MP/E –Yield 0.00%

Latigo Biotherapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Latigo Biotherapeutics's enterprise value was -$41.64M on Nov 11, 2026.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$41.64M–

More Latigo Biotherapeutics figures

See a number that looks wrong?